Drug Information

Drug General Information
Drug ID
D04OMR
Former ID
DNCL001630
Drug Name
PF-04840082
Indication Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] Phase 1 [523352]
Company
Pfizer New York, NY
Target and Pathway
Target(s) DKK1 protein Target Info Modulator [530645]
KEGG Pathway Wnt signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Wnt Signaling Pathway
FSH Signaling Pathway
Pathway Interaction Database Presenilin action in Notch and Wnt signaling
Wnt signaling network
Direct p53 effectors
Regulation of nuclear beta catenin signaling and target gene transcription
Validated targets of C-MYC transcriptional repression
Reactome TCF dependent signaling in response to WNT
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
WikiPathways Mesodermal Commitment Pathway
Endoderm Differentiation
Differentiation Pathway
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Primary Focal Segmental Glomerulosclerosis FSGS
Cardiac Progenitor Differentiation
References
Ref 523352ClinicalTrials.gov (NCT01293487) Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.. U.S. National Institutes of Health.
Ref 530645The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.